H. Elnahas

Bridging the Lab-to-Clinic Gap in Intranasal Nanomaterial-Based Chemotherapy for Glioblastoma

Clinical outcomes for brain cancer are often poor because the blood–brain/tumor barrier hinders effective drug delivery to malignant tissue. Glioblastoma, the most common primary brain malignancy in adults, has an average survival of approximately fourteen months. Here, we discuss novel strategies that our research gro...